87 related articles for article (PubMed ID: 9815170)
1. Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR; DeGrado TR
Bioconjug Chem; 1998; 9(6):758-64. PubMed ID: 9815170
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
4. No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Appl Radiat Isot; 2005 Mar; 62(3):435-40. PubMed ID: 15607920
[TBL] [Abstract][Full Text] [Related]
5. 99mTc-labeled MIBG derivatives: novel 99mTc complexes as myocardial imaging agents for sympathetic neurons.
Zhuang ZP; Kung MP; Mu M; Hou C; Kung HF
Bioconjug Chem; 1999; 10(2):159-68. PubMed ID: 10077463
[TBL] [Abstract][Full Text] [Related]
6. A convenient method for the preparation of radioiodinated meta-iodobenzylguanidine at a no-carrier-added level.
Wang G; Chen Z; Wu E; Wang Y; Huang H
J Labelled Comp Radiopharm; 2015; 58(11-12):442-4. PubMed ID: 26391308
[TBL] [Abstract][Full Text] [Related]
7. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
8. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
Vaidyanathan G; Shankar S; Affleck DJ; Alston K; Norman J; Welsh P; LeGrand H; Zalutsky MR
Bioorg Med Chem; 2004 Apr; 12(7):1649-56. PubMed ID: 15028258
[TBL] [Abstract][Full Text] [Related]
9. Potential and practical adrenomedullary PET radiopharmaceuticals as an alternative to m-iodobenzylguanidine: m-(omega-[18F]fluoroalkyl)benzylguanidines.
Lee BC; Paik JY; Chi DY; Lee KH; Choe YS
Bioconjug Chem; 2004; 15(1):104-11. PubMed ID: 14733589
[TBL] [Abstract][Full Text] [Related]
10. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
11. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR
Appl Radiat Isot; 1993 Mar; 44(3):621-8. PubMed ID: 8472027
[TBL] [Abstract][Full Text] [Related]
12. Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma.
Altmann A; Kissel M; Zitzmann S; Kübler W; Mahmut M; Peschke P; Haberkorn U
J Nucl Med; 2003 Jun; 44(6):973-80. PubMed ID: 12791828
[TBL] [Abstract][Full Text] [Related]
13. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of
Das S; Sakhare N; Mathur A; Mallia MB; Mirapurkar S; Sheela M; Sarma HD; Sachdev SS; Dash A
Nucl Med Biol; 2019; 68-69():49-57. PubMed ID: 30770228
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues.
Vaidyanathan G; Shankar S; Affleck DJ; Welsh PC; Slade SK; Zalutsky MR
Bioconjug Chem; 2001; 12(5):798-806. PubMed ID: 11562198
[TBL] [Abstract][Full Text] [Related]
16. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
[TBL] [Abstract][Full Text] [Related]
17. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats.
Kiyono Y; Iida Y; Kawashima H; Ogawa M; Tamaki N; Nishimura H; Saji H
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):999-1005. PubMed ID: 12173012
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues.
Vaidyanathan G; Shankar S; Zalutsky MR
Bioconjug Chem; 2001; 12(5):786-97. PubMed ID: 11562197
[TBL] [Abstract][Full Text] [Related]
19. [A simple and rapid routine preparation of no-carrier added meta-I-123- and I-131-iodobenzylguanidine (I-123-MIBG and I-131-MIBG) for clinical nuclear medicine applications].
Samnick S; Kirsch CM
Nuklearmedizin; 1999; 38(7):292-6. PubMed ID: 10599069
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine Improves Imaging and Targeted Radionuclide Therapy of Norepinephrine Transporter-Expressing Tumors.
Yamaguchi A; Hanaoka H; Higuchi T; Tsushima Y
J Nucl Med; 2018 May; 59(5):815-821. PubMed ID: 29217738
[No Abstract] [Full Text] [Related]
[Next] [New Search]
